FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156823809> ?p ?o ?g. }

• W2156823809 endingPage "6" @default.
• W2156823809 startingPage "1051" @default.
• W2156823809 abstract "A multicenter Phase II trial was performed to investigate the efficacy and tolerance of combined docetaxel and gemcitabine +/- recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with metastatic breast cancer.Fifty-two patients participated in this trial, 51 of whom are evaluable for response. Thirty-eight patients received this combination as first-line chemotherapy, and 14 patients received this combination as second-line chemotherapy, including 10 patients who had failed anthracyclines. Therapy consisted of 1500 mg/m2 gemcitabine and 50 mg/m2 docetaxel, both administered on days 1 and 15 every 4 weeks. Depending on the absolute neutrophil counts on the day of scheduled chemotherapeutic drug administration, a 5-day course of 5 microg/kg G-CSF was given.The overall response rate was 60.5% (95% confidence interval, 43.4-75.9%) in patients receiving docetaxel plus gemcitabine as first-line chemotherapy, including 4 complete responses (10.5%) and 19 partial remissions (50%); 9 patients (24%) had disease stabilization, and only 5 (13%) progressed. Second-line treatment with this regimen resulted in 6 of 14 (43%) objective responses, 5 had stable disease, and 3 progressive disease. The median time to progression was 8.5 months in the first-line setting and 6.6 months in the second-line setting, respectively. After a median follow-up time of 15 months, 36 patients (69%) are still alive with metastatic disease. Myelosuppression was commonly observed; WHO grade 3 or 4 neutropenia, however, occurred in only 15 (29%) patients and was complicated by septicemia in 2 cases; grade 3 anemia was seen in 1 patient (2%). Severe (grade 3) nonhematological toxicity except for alopecia was rarely observed and included nausea/vomiting in 3 (6%), stomatitis in 2 (4%), anaphylaxis in 2, and peripheral neuropathy, skin toxicity, and increase of liver enzymes each in one patient.Our data suggest that docetaxel and gemcitabine with and without G-CSF is an effective and fairly well-tolerated regimen for the treatment of advanced breast cancer. It might be particularly useful in patients exposed previously to adjuvant or palliative anthracyclines and/or alkylating agents." @default.
• W2156823809 created "2016-06-24" @default.
• W2156823809 creator A5002926775 @default.
• W2156823809 creator A5010712142 @default.
• W2156823809 creator A5014692801 @default.
• W2156823809 creator A5024985025 @default.
• W2156823809 creator A5031817523 @default.
• W2156823809 creator A5044117633 @default.
• W2156823809 creator A5079062938 @default.
• W2156823809 creator A5080521503 @default.
• W2156823809 creator A5090007752 @default.
• W2156823809 creator A5091410812 @default.
• W2156823809 date "2002-05-01" @default.
• W2156823809 modified "2023-09-24" @default.
• W2156823809 title "Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor." @default.
• W2156823809 cites W1812067939 @default.
• W2156823809 cites W1830813972 @default.
• W2156823809 cites W1858072261 @default.
• W2156823809 cites W1863320839 @default.
• W2156823809 cites W1898988182 @default.
• W2156823809 cites W1907604566 @default.
• W2156823809 cites W1942454844 @default.
• W2156823809 cites W1971473564 @default.
• W2156823809 cites W1972637700 @default.
• W2156823809 cites W1974775787 @default.
• W2156823809 cites W1979300931 @default.
• W2156823809 cites W1989339760 @default.
• W2156823809 cites W1996862533 @default.
• W2156823809 cites W2024210946 @default.
• W2156823809 cites W2036067444 @default.
• W2156823809 cites W2036953678 @default.
• W2156823809 cites W2067437759 @default.
• W2156823809 cites W2154094988 @default.
• W2156823809 cites W2154737435 @default.
• W2156823809 cites W2167805334 @default.
• W2156823809 cites W2168902572 @default.
• W2156823809 cites W2169073956 @default.
• W2156823809 cites W2228069427 @default.
• W2156823809 cites W2229518396 @default.
• W2156823809 cites W2318605753 @default.
• W2156823809 cites W2414066636 @default.
• W2156823809 cites W2418853205 @default.
• W2156823809 cites W2991656315 @default.
• W2156823809 cites W73784268 @default.
• W2156823809 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12006518" @default.
• W2156823809 hasPublicationYear "2002" @default.
• W2156823809 type Work @default.
• W2156823809 sameAs 2156823809 @default.
• W2156823809 citedByCount "15" @default.
• W2156823809 countsByYear W21568238092018 @default.
• W2156823809 crossrefType "journal-article" @default.
• W2156823809 hasAuthorship W2156823809A5002926775 @default.
• W2156823809 hasAuthorship W2156823809A5010712142 @default.
• W2156823809 hasAuthorship W2156823809A5014692801 @default.
• W2156823809 hasAuthorship W2156823809A5024985025 @default.
• W2156823809 hasAuthorship W2156823809A5031817523 @default.
• W2156823809 hasAuthorship W2156823809A5044117633 @default.
• W2156823809 hasAuthorship W2156823809A5079062938 @default.
• W2156823809 hasAuthorship W2156823809A5080521503 @default.
• W2156823809 hasAuthorship W2156823809A5090007752 @default.
• W2156823809 hasAuthorship W2156823809A5091410812 @default.
• W2156823809 hasConcept C121608353 @default.
• W2156823809 hasConcept C126322002 @default.
• W2156823809 hasConcept C141071460 @default.
• W2156823809 hasConcept C143998085 @default.
• W2156823809 hasConcept C2775930923 @default.
• W2156823809 hasConcept C2776694085 @default.
• W2156823809 hasConcept C2777063308 @default.
• W2156823809 hasConcept C2777767877 @default.
• W2156823809 hasConcept C2778336483 @default.
• W2156823809 hasConcept C2778397455 @default.
• W2156823809 hasConcept C2778822529 @default.
• W2156823809 hasConcept C2780258809 @default.
• W2156823809 hasConcept C2781190966 @default.
• W2156823809 hasConcept C2781413609 @default.
• W2156823809 hasConcept C31760486 @default.
• W2156823809 hasConcept C530470458 @default.
• W2156823809 hasConcept C71924100 @default.
• W2156823809 hasConcept C90924648 @default.
• W2156823809 hasConceptScore W2156823809C121608353 @default.
• W2156823809 hasConceptScore W2156823809C126322002 @default.
• W2156823809 hasConceptScore W2156823809C141071460 @default.
• W2156823809 hasConceptScore W2156823809C143998085 @default.
• W2156823809 hasConceptScore W2156823809C2775930923 @default.
• W2156823809 hasConceptScore W2156823809C2776694085 @default.
• W2156823809 hasConceptScore W2156823809C2777063308 @default.
• W2156823809 hasConceptScore W2156823809C2777767877 @default.
• W2156823809 hasConceptScore W2156823809C2778336483 @default.
• W2156823809 hasConceptScore W2156823809C2778397455 @default.
• W2156823809 hasConceptScore W2156823809C2778822529 @default.
• W2156823809 hasConceptScore W2156823809C2780258809 @default.
• W2156823809 hasConceptScore W2156823809C2781190966 @default.
• W2156823809 hasConceptScore W2156823809C2781413609 @default.
• W2156823809 hasConceptScore W2156823809C31760486 @default.
• W2156823809 hasConceptScore W2156823809C530470458 @default.
• W2156823809 hasConceptScore W2156823809C71924100 @default.
• W2156823809 hasConceptScore W2156823809C90924648 @default.
• W2156823809 hasIssue "5" @default.

• next